Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Ixabepilone and Cetuximab in Advanced NSCLC
NCT00998101Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jul 2009
- Primary completion
- Nov 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone and cetuximab in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Disease-control rate at 42 days. Planned start Jul 2009; status: withdrawn.
02
Drugs
ixabepilonecetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00998101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998101.